Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.
Tanaka
Toshihiro
T
Motherisk Program, Division of Clinical Pharmacology and Toxicology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto ON. shinya.ito@sickkids.ca
Nakajima
Ken
K
Murashima
Atsuko
A
Garcia-Bournissen
Facundo
F
Koren
Gideon
G
Ito
Shinya
S
D001942:Breast Feeding; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D007251:Influenza, Human / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D007774:Lactation / Q000187:drug effects; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053139:Oseltamivir / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000201:enzymology; D016896:Treatment Outcome; D014765:Viral Vaccines / Q000627:therapeutic use*; D053243:Zanamivir / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D014765:Viral Vaccines; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir